imatinib mesylate has been researched along with Thrombopenia in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bett, Y; Ezzi, M; McLigeyo, A; Mwanzi, S; Odhiambo, A; Ong'ondi, M; Othieno-Abinya, N; Oyiro, P; Rajab, J | 1 |
| Itoh, Y; Nakamura, Y; Wakimoto, N | 1 |
| Aleem, A; AlFaifi, A; Alotaibi, G; Iqbal, Z | 1 |
| Choi, SY; Jung, SY; Kee, KM; Kim, DW; Kim, SH; Lee, JI; Noh, H; Shin, H; Yang, SY; Zang, DY | 1 |
| Bunworasate, U; Caguioa, PB; Choi, CW; Chung, JS; Comia, NS; Do, YR; Jootar, S; Jung, CW; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kong, JH; Kwak, JY; Lee, SE; Lee, WS; Mun, YC; Oh, SJ; Park, J; Park, JS; Reksodiputro, AH; Shin, HJ; Zang, DY | 1 |
| Bhat, M; Gupta, N; Guru, SA; Masroor, M; Mir, R; Najar, I; Saxena, A; Sumi, M; Zuberi, M | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Abdelaal, M; Abrar, MB; Absi, A; Al-Amri, A; Alsaeed, A; Alshehri, MA; Alsobhi, E; Alzahrani, Z; Bayashoot, S; El-Hemaidi, I; Hashem, H; Merdad, A; Radi, S; Shiekhi, H; Warsi, A | 1 |
| DU, X; Han, X; Hou, M; Hu, J; Jiang, Q; Jin, J; Li, Y; Liu, B; Liu, T; Ma, J; Meng, F; Shen, Z; Wu, D; Zhao, D | 1 |
| Chandrasekaran, A; Dubashi, B; Francis, J; Pradhan, SC; Sundaram, R | 1 |
| Aribi, A; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Koller, C; Thomas, D | 1 |
| Fujiwara, H; Hayama, BY; Iwama, K; Kimura, S; Matsue, K; Matsuo, K; Takeuch, M; Yamakura, M | 1 |
| Calbacho, M; Cervantes, F; Colomer, D; González, M; Hernández-Boluda, JC; Jonte, F; López-Garrido, P; Martínez, J; Montero, MI; Nieto, JB; Pereira, A; Pérez-López, C; Pérez-Rus, G; Román-Gómez, J; Sureda, A | 1 |
| Bakhshi, S; Gupta, R; Kumar, L; Kumar, R; Medhi, K; Raina, V; Sharma, A | 1 |
| Allard, C; Berger, M; Berthou, C; Coiteux, V; Corm, S; Delmer, A; Eclache, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Jourdan, E; Legros, L; Mahon, FX; Maloisel, F; Nicolini, FE; Preudhomme, C; Rea, D; Rigal-Huguet, F; Roche-Lestienne, C; Rousselot, P; Vekhoff, A | 1 |
| Bang, SM; Cheong, JW; Chung, JS; Eom, KS; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, DH; Kim, H; Kim, HJ; Kim, MK; Kim, YK; Lee, HG; Min, YH; Moon, JH; Oh, SJ; Park, EK; Park, J; Park, JS; Park, MR; Park, SY; Ryoo, HM; Sohn, SK; Won, JH; Yoon, SS; Zang, DY | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Hawkes, EA; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Jiang, QL; Meng, FY; Shu, LL; Yang, M | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL | 1 |
| Berkowitz, LR; Dunphy, CH; Hall, MD; Hogan, C; Koehler, J; Mitchell, BS; Orlowski, RZ; Shea, TC; van Deventer, HW | 1 |
| Gotoh, A; Ito, Y; Katagiri, T; Kawakubo, K; Kawanishi, Y; Kimura, Y; Kuriyama, Y; Miyazawa, K; Nishimaki, J; Ohyashiki, K; Sashida, G; Shimamoto, T; Shoji, N; Suzuki, A; Tauchi, T | 1 |
| Apperley, JF; Bua, M; Foot, N; Goldman, JM; Marin, D; Marktel, S | 1 |
| Campbell, L; Grigg, A; Hoyt, R; Juneja, S; Lynch, K; McNamara, C; Roberts, A; Szer, J | 1 |
| Chen, S; Huang, X; Jiang, B; Jiang, H; Jiang, Q; Lu, D; Lu, Y | 1 |
| Berthaud, P; Berthou, C; Buzyn, A; Cheron, N; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M | 1 |
| Carrasco, M; Conde, E; de Miguel, M; Díaz-Mediavilla, J; Martínez, JA; Sanz, MA; Sierra, J; Sureda, A | 1 |
| Bekele, BN; Cortes, JE; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Sneed, TB; Talpaz, M; Wierda, W; Zhou, X | 1 |
| Ault, P; Cortes, J; Giles, F; Kantarjian, H; Rios, MB; Welch, MA | 1 |
| Al-Beirouti, B; Keating, A; Lipton, JH; McCrae, J; Messner, HA; Rifkind, J; Song, KW; Yee, K | 1 |
| Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C | 1 |
| Baccarani, M; Cortes, J; Deininger, MW; Druker, BJ; Fischer, T; Gambacorti-Passerini, C; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Kantarjian, H; Niederwieser, D; Paquette, R; Park, B; Smith, D; So, C; Stone, R | 1 |
| Abdulhaq, H; Jalil, A; Lister, J; Makary, A; Rossetti, J; Shadduck, RK; Talreja, N | 1 |
| Choi, CW; Choi, IK; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Park, SJ; Seo, HY; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Busuttil, DP | 1 |
2 review(s) available for imatinib mesylate and Thrombopenia
| Article | Year |
|---|---|
[Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
Topics: Antineoplastic Agents; Benzamides; Caspase 3; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Thrombocytopenia; Thrombopoiesis | 2011 |
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors | 2012 |
13 trial(s) available for imatinib mesylate and Thrombopenia
| Article | Year |
|---|---|
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Topics: Adult; Benzamides; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thrombocytopenia; Treatment Outcome | 2017 |
[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytogenetics; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors; Remission Induction; Thrombocytopenia; Treatment Outcome | 2015 |
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Spain; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2010 |
Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome; Young Adult | 2010 |
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Polyethylene Glycols; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombinant Proteins; Remission Induction; RNA, Neoplasm; Stem Cells; Survival Analysis; Thrombocytopenia; Transcription, Genetic; Treatment Outcome | 2010 |
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Logistic Models; Male; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thrombocytopenia; Time Factors; Transcription, Genetic; Treatment Outcome; Young Adult | 2011 |
A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Count; Cytogenetic Analysis; Disease Progression; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Megakaryocytes; Piperazines; Pyrimidines; Thrombocytopenia; Time Factors | 2002 |
Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Count; Cytogenetic Analysis; Drug Resistance; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Reticulin; Thrombocytopenia; Treatment Outcome | 2003 |
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Safety; Thrombocytopenia | 2003 |
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease-Free Survival; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Risk Factors; Thrombocytopenia; Treatment Outcome | 2004 |
20 other study(ies) available for imatinib mesylate and Thrombopenia
| Article | Year |
|---|---|
Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Kenya; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2022 |
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
Topics: Adrenal Cortex Hormones; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prednisolone; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia.
Topics: Female; Humans; Imatinib Mesylate; Intracranial Hemorrhages; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Thrombocytopenia; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Body Weight; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Precision Medicine; Safety; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2020 |
PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors; Thrombocytopenia | 2017 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Retrospective Studies; Saudi Arabia; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chromatography, Liquid; Female; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transporter 1; Polymorphism, Single Nucleotide; Tandem Mass Spectrometry; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interleukin-11; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pilot Projects; Piperazines; Platelet Count; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thrombocytopenia; Treatment Outcome | 2008 |
Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
Topics: Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Agents; Benzamides; Blood Coagulation Tests; Cross-Sectional Studies; Female; Follow-Up Studies; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thrombocytopenia; Treatment Outcome; Withholding Treatment | 2009 |
Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thrombocytopenia | 2003 |
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Benzamides; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Thrombocytopenia | 2003 |
[Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients].
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Risk Factors; Thrombocytopenia; Treatment Outcome | 2003 |
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Interleukin-11; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Count; Protein-Tyrosine Kinases; Pyrimidines; Thrombocytopenia; Time Factors | 2004 |
Subdural hematomas during CML therapy with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Risk Factors; Thrombocytopenia; Treatment Outcome | 2004 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance; Enzyme Inhibitors; Gene Rearrangement; Humans; Hydroxyurea; Imatinib Mesylate; Leukocytosis; Male; Middle Aged; Mutant Proteins; Oncogene Proteins, Fusion; Piperazines; Primary Myelofibrosis; Pyrimidines; Splenectomy; Splenomegaly; Thrombocytopenia; Translocation, Genetic; Treatment Failure | 2004 |
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Chromosome Aberrations; Chronic Disease; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Logistic Models; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Piperazines; Prognosis; Pyrimidines; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2007 |
Erythroid variant of chronic myelogenous leukemia.
Topics: Adult; Benzamides; Diagnosis, Differential; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Remission Induction; Thrombocytopenia | 2008 |
Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Dose-Response Relationship, Drug; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thrombocytopenia | 2007 |
Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Busulfan; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Survivors; Thrombocytopenia | 2008 |